Literature DB >> 11929784

The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells.

Carole L Berger1, Douglas Hanlon, Daniel Kanada, Madhav Dhodapkar, Vivian Lombillo, Nianci Wang, Inger Christensen, Gregory Howe, Jill Crouch, Paul El-Fishawy, Richard Edelson.   

Abstract

In the initial stage of cutaneous T-cell lymphoma (CTCL), proliferating CTCL cells are concentrated in the epidermis in close association with an immature dendritic cell (DC), the Langerhans cell. Because long-term in vitro culture of CTCL cells has proven difficult, the in vivo association with the major antigen-presenting cell (APC) of the epidermis has been postulated to play a role in directly stimulating the clonal T-cell proliferation. We report that CTCL cells can be reproducibly grown in culture for 3 months when cocultured with immature DCs. CTCL cells retain the phenotype and genotype of the initial malignant clone, whereas the APCs are a mixture of immature and mature DCs. CTCL cell and DC survival was dependent on direct membrane contact. Growth was inhibited by antibodies that bound to the T-cell receptor (TCR) or interfered with the interaction of CD40 with its ligand on the CTCL cell. Addition of antibody to CD3 or the clonotypic TCR caused rapid CTCL cell apoptosis followed by engulfment by avidly phagocytic immature DCs and subsequent DC maturation. The opportunity to study CTCL cells and immature DCs for prolonged periods will facilitate studies of tumor cell biology and will allow investigation of the intriguing hypothesis that CTCL cell growth is driven through TCR recognition of class II-presented self-peptides. In addition, the culture of CTCL cells will permit evaluation of therapies in vitro before clinical intervention, thereby improving safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11929784

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  31 in total

1.  Endogenous dendritic cells from the tumor microenvironment support T-ALL growth via IGF1R activation.

Authors:  Todd A Triplett; Kim T Cardenas; Jessica N Lancaster; Zicheng Hu; Hilary J Selden; Guadalupe J Jasso; Sadhana Balasubramanyam; Kathy Chan; LiQi Li; Xi Chen; Andrea N Marcogliese; Utpal P Davé; Paul E Love; Lauren I R Ehrlich
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-09       Impact factor: 11.205

Review 2.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

3.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.

Authors:  Carlos Murga-Zamalloa; Delphine C M Rolland; Avery Polk; Ashley Wolfe; Hiran Dewar; Pinki Chowdhury; Ozlem Onder; Rajan Dewar; Noah A Brown; Nathanael G Bailey; Kedar Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

Review 4.  Mycosis Fungoides and Sézary Syndrome: An Update.

Authors:  Cecilia Larocca; Thomas Kupper
Journal:  Hematol Oncol Clin North Am       Date:  2019-02       Impact factor: 3.722

Review 5.  Cutaneous T-cell lymphoma: Biologic targets for therapy.

Authors:  Jaehyuk Choi; Francine Foss
Journal:  Curr Hematol Malig Rep       Date:  2007-10       Impact factor: 3.952

6.  Depletion of M2-like tumor-associated macrophages delays cutaneous T-cell lymphoma development in vivo.

Authors:  Xuesong Wu; Brian C Schulte; Youwen Zhou; Dipica Haribhai; Alexander C Mackinnon; Jose A Plaza; Calvin B Williams; Sam T Hwang
Journal:  J Invest Dermatol       Date:  2014-04-29       Impact factor: 8.551

7.  The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.

Authors:  Ce Tiffon; Je Adams; L van der Fits; S Wen; Pa Townsend; A Ganesan; E Hodges; Mh Vermeer; G Packham
Journal:  Br J Pharmacol       Date:  2011-04       Impact factor: 8.739

Review 8.  Immunopathogenesis and therapy of cutaneous T cell lymphoma.

Authors:  Ellen J Kim; Stephen Hess; Stephen K Richardson; Sara Newton; Louise C Showe; Bernice M Benoit; Ravi Ubriani; Carmela C Vittorio; Jacqueline M Junkins-Hopkins; Maria Wysocka; Alain H Rook
Journal:  J Clin Invest       Date:  2005-04       Impact factor: 14.808

9.  Myeloid dendritic cells from human cutaneous squamous cell carcinoma are poor stimulators of T-cell proliferation.

Authors:  Mark J Bluth; Lisa C Zaba; Dariush Moussai; Mayte Suárez-Fariñas; Helen Kaporis; Linda Fan; Katherine C Pierson; Traci R White; Alexander Pitts-Kiefer; Judilyn Fuentes-Duculan; Emma Guttman-Yassky; James G Krueger; Michelle A Lowes; John A Carucci
Journal:  J Invest Dermatol       Date:  2009-04-23       Impact factor: 8.551

10.  Update on the treatment of cutaneous T-cell lymphoma (CTCL): Focus on vorinostat.

Authors:  Madeleine Duvic; Jenny Vu
Journal:  Biologics       Date:  2007-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.